Masimo and MS Westfalia GmbH (MSW) Expand Partnership to Add Masimo SedLine® Brain Function Monitoring, O3® Regional Oximetry, and Oxygen Reserve Index (ORi™) to the MSW Modular Point-of-Care Hybrid Jenny

Jenny Combines Ventilation and Multi-Parameter Monitoring and Defibrillation in a Single Point-of-Care Device, Including Masimo rainbow SET® Measurements, NomoLine® Capnography, and now Brain Monitoring Technologies – The World’s First All-in-One Solution of Its Kind

IRVINE, Calif. & TROISDORF, Germany-Friday 28 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) and MS Westfalia GmbH (MSW) announced today that MSW will integrate additional Masimo measurement technologies into MSW’s plug-and-play hybrid Jenny platform, to help clinicians assess brain function, oxygenation, ventilation, and resuscitation status.

After launching the Jenny modular point-of-care monitoring device with integrated Masimo noninvasive, continuous rainbow SET® measurements (including total hemoglobin, SpHb®) and Masimo sidestream and mainstream NomoLine® capnography, MSW plans to add Masimo Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and Oxygen Reserve Index (ORi™) to Jenny. By doing so, MSW will make the platform an even more versatile and comprehensive monitoring solution, suitable for use in a variety of care areas, including the ICU and the OR, as well as in EMS and military settings.

The three additional technologies, currently available directly from Masimo on the Root® Patient Monitoring and Connectivity Platform, are:

Next Generation SedLine Brain Function Monitoring, which assists clinicians in monitoring the state of the brain under anesthesia, with bilateral data acquisition and processing of EEG signals and an enhanced Patient State Index (PSi).
O3 Regional Oximetry, which may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.
ORi, the first noninvasive and continuous parameter to provide insight into the oxygen reserve of patients receiving supplemental oxygen.
Eugen Kagan, CEO of MSW, said, “Our company’s mission is to save lives and improve quality of life for our patients. For more than 25 years, our goal has been to develop products that assist healthcare providers in the hospital and pre-hospital markets by helping to improve patient outcomes and increase patient satisfaction and workflow efficiency – while lowering the cost of healthcare. We accomplish this by developing revolutionary approaches to new product development and by partnering with best-in-class partners like Masimo so we may meet the needs of a constantly changing healthcare landscape. The expanded technology partnership between MSW and Masimo allows us to offer our customers the most innovative technologies, helping them overcome many of the daily challenges they face in healthcare delivery.”

Joe Kiani, Founder and CEO of Masimo, said, “It’s great to see MSW’s commitment to incorporating our full suite of noninvasive, continuous measurements into their all-in-one modular Jenny platform. We are happy to be able to help MSW accomplish its wonderful mission.”

ORi has obtained CE marking and is not available in the U.S.

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-6 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,7 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S. News and World Report Best Hospitals Honor Roll.8 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Doctella™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
Estimate: Masimo data on file.
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
About MSW

MS Westfalia GmbH is one of the largest distributors of medical equipment on the market in Central Europe and the CIS. The company was founded in 1995. Since then, successful business allowed the company not only to develop the promotion of world famous brands, but also to begin its own production of high-tech medical devices.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SedLine®, O3®, ORi™, rainbow SET®, NomoLine®, and Root®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SedLine, O3, ORi, rainbow SET, and NomoLine, and Root, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200225005103/en/

Contacts
Media Contacts:
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

MSW                         
Julia Artel
+49 2241 944 933
j.artel@mswestfalia.de


Permalink : https://www.aetoswire.com/news/masimo-and-ms-westfalia-gmbh-msw-expand-partnership-to-add-masimo-sedlineregnbspbrain-function-monitoring-o3regnbspregional-oximetry-and-oxygen-reserve-index-oritrade-to-the-msw-modular-point-of-care-hybrid-jenny/en

Schlumberger Announces First-Quarter 2020 Results Conference Call

PARIS-Saturday 29 February 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- Schlumberger Limited (NYSE: SLB) will hold a conference call on April 17, 2020 to discuss the results for the first quarter ending March 31, 2020.

The conference call is scheduled to begin at 8:30 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time.

To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483.

A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402) 970-0847 outside of North America, and giving the access code 8905486.

About Schlumberger

Schlumberger is the world’s leading provider of technology for reservoir characterization, drilling, production, and processing to the oil and gas industry. With product sales and services in more than 120 countries and employing approximately 105,000 people who represent over 170 nationalities, Schlumberger supplies the industry’s most comprehensive range of products and services, from exploration through production, and integrated pore-to-pipeline solutions that optimize hydrocarbon recovery to deliver reservoir performance sustainably.

Schlumberger Limited has executive offices in Paris, Houston, London, and The Hague, and reported revenues of $32.92 billion in 2019. For more information, visit www.slb.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005987/en/

Contacts

Simon Farrant – Vice President of Investor Relations, Schlumberger Limited
Joy V. Domingo – Director of Investor Relations, Schlumberger Limited

Office +1 (713) 375-3535
investor-relations@slb.com


Permalink : https://www.aetoswire.com/news/schlumberger-announces-first-quarter-2020-results-conference-call/en

AURAK Signs Deal with British Council to Act as Exam Center

RAS AL KHAIMAH, United Arab Emirates-Monday 24 February 2020 [ AETOS Wire ]

The American University of Ras Al Khaimah (AURAK) and the British Council have signed an agreement for AURAK to act as a center for the IELTS exam administered by the British Council.

The International English Language Testing System (IELTS) is an international standardized test of English language proficiency for non-native speakers of English.

Under the agreement, AURAK will provide information to potential candidates about the IELTS, register candidates, and act as the venue for the test. According to the deal, the British Council will be responsible for administering the exams.

President of AURAK, Professor Hassan Hamdan Al Alkim, signed the deal on behalf of the University and Mr. Deep Adhikari did so for the British Council. The deal is due to run until the end of 2020 but can be extended by mutual agreement.

The British Council also agreed to cooperate in future with AURAK in liaising with British universities.

AURAK’s agreement with the British Council fits in with the University’s policy of expanding services and facilities for students. A bookshop and two cafés recently opened on the AURAK campus and further development is in progress.

The British Council is the United Kingdom’s international organization for cultural relations and educational opportunities. It teaches English and holds exams around the world.

AURAK is a nonprofit, government-owned institution of higher education which provides the local, regional and international communities with a North American-style education integrated with Arab customs and traditions. AURAK is licensed by the Ministry of Education in the United Arab Emirates and has been accredited in the United States of America by Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) since December 2018. AURAK offers a total of 22 accredited undergraduate and graduate programs across a wide range of disciplines.

Contacts
AURAK

Kamel Abu-Youssef, Direct: +97172468806

k.youssef@aurak.ac.ae

Permalink : https://www.aetoswire.com/news/aurak-signs-deal-with-british-council-to-act-as-exam-center/en

Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

− If approved, the additional treatment modality will provide more options for how patients in Europe receive the gut-selective biologic vedolizumab

− Recommendation brings vedolizumab one step closer to becoming the only maintenance therapy with both intravenous and subcutaneous formulation options for patients with ulcerative colitis or Crohn’s disease

OSAKA, Japan-Friday 28 February 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). Takeda proposes to make vedolizumab SC available in both a pre-filled syringe and a pre-filled pen.

The CHMP opinion will now be reviewed by the European Commission. If approved, vedolizumab will become the only maintenance therapy for UC or CD with both intravenous and subcutaneous formulations across the European Union, providing greater options for how patients receive their treatment.

“Today’s positive CHMP opinion marks a key step forward in our goal to provide greater options to patients with ulcerative colitis and Crohn’s disease,” said Adam Zaeske, Head, GI Franchise, Europe and Canada Business Unit, Takeda. “Ulcerative colitis and Crohn’s disease are life-long diseases and it is important that patients have treatment options that suit their different preferences and lifestyles. We look forward to the European Commission’s decision and the opportunity to bring a subcutaneous formulation of vedolizumab to these patients across Europe.”

The positive opinion from the CHMP was based on the pivotal phase 3 VISIBLE trials which assessed the safety and efficacy of a SC formulation of vedolizumab as maintenance therapy in adult patients with moderately to severely active UC or CD who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) therapy at weeks 0 and 2.1,2,3 Data from a long-term, open-label extension study of patients from VISIBLE 1 and VISIBLE 2 was also considered.4

* VISIBLE 1 UC: Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from baseline (week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.2

VISIBLE 2 CD: Clinical response is defined as a ≥70 point decrease in Crohn's Disease Activity Index (CDAI) score from baseline (week 0).5

About the VISIBLE Clinical Trial Program
The VISIBLE clinical trial program aims to assess the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab as maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD).

The VISIBLE program consists of three phase 3 studies involving over 1,000 UC and CD patients which includes two randomized, double-blind, placebo-controlled studies examining the proportion of patients achieving clinical remission at week 52, and an open-label extension study to determine the long-term safety and efficacy of vedolizumab SC.2,3,4

About Ulcerative Colitis and Crohn’s Disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are two of the most common forms of inflammatory bowel disease (IBD).6 Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal tract, with CD potentially progressing over time.7,8 UC only involves the large intestine as opposed to CD which can affect any part of the GI tract from mouth to anus.9,10 CD can also affect the entire thickness of the bowel wall while UC only involves the innermost lining of the large intestine.9,10 UC commonly presents with symptoms of abdominal discomfort, loose bowel movements, including blood or pus.9,11 CD commonly presents with symptoms of abdominal pain, diarrhea, and weight loss.7 The cause of UC or CD is not fully understood; however, recent research suggests hereditary, genetics, environmental factors, and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to UC or CD.9,12,13

About Entyvio® (vedolizumab)
Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.14,15 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).16 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.17 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.16 These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn’s disease (CD).16,18,19 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.16

Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα)-antagonist.14,15 Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with more than 415,000 patient years of exposure to date.5

Therapeutic Indications for vedolizumab IV

Ulcerative colitis
Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Crohn’s disease
Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Important Safety Information for vedolizumab IV

Contraindications
Hypersensitivity to the active substance or to any of the excipients.

Special warnings and special precautions for use
Vedolizumab should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering vedolizumab. Observe patients during infusion and until the infusion is complete.

Infusion-related reactions
In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity. If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of vedolizumab must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines). If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated (e.g., epinephrine and antihistamines). Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab, in order to minimize their risks.

Infections
Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity. Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier. Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab. Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Before starting treatment with vedolizumab, screening for tuberculosis may be considered according to local practice. Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the α4β7 integrin expressed on gut-homing lymphocytes, vedolizumab exerts an immunosuppressive effect specific to the gut. Although no systemic immunosuppressive effect was noted in healthy subjects, the effects on systemic immune system function in patients with inflammatory bowel disease are not known. Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur. If PML is suspected, treatment with vedolizumab must be withheld; if confirmed, treatment must be permanently discontinued. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. The progression of deficits usually leads to death or severe disability over weeks or months.

Malignancies
The risk of malignancy is increased in patients with ulcerative colitis and Crohn’s disease. Immunomodulatory medicinal products may increase the risk of malignancy.

Prior and concurrent use of biological products
No vedolizumab clinical trial data are available for patients previously treated with natalizumab. No clinical trial data for concomitant use of vedolizumab with biologic immunosuppressants are available. Therefore, the use of vedolizumab in such patients is not recommended.

Vaccinations
Prior to initiating treatment with vedolizumab all patients should be brought up to date with all recommended immunizations. Patients receiving vedolizumab may receive non-live vaccines (e.g., subunit or inactivated vaccines) and may receive live vaccines only if the benefits outweigh the risks.

Adverse reactions include: nasopharyngitis, headache, arthralgia, upper respiratory tract infection, bronchitis, influenza, sinusitis, cough, oropharyngeal pain, nausea, rash, pruritus, back pain, pain in extremities, pyrexia, fatigue and anaphylaxis.

Please consult with your local regulatory agency for approved labeling in your country.
For U.S. audiences, please see the full Prescribing Information, including Medication Guide for ENTYVIO®.
For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO®.

Takeda’s Commitment to Gastroenterology
Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit https://www.takeda.com

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

###

References

1 Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of a new vedolizumab subcutaneous formulation in ulcerative colitis: VISIBLE 1 randomized trial. Gastroenterology. 2019. DOI: https://doi.org/10.1053/j.gastro.2019.08.027.

2 Efficacy and safety of vedolizumab subcutaneously (SC) as maintenance therapy in ulcerative colitis. Available at: https://clinicaltrials.gov/ct2/show/NCT02611830. Last updated: January 23, 2020. Last accessed: February 2020.

3 Efficacy and safety of vedolizumab subcutaneous (SC) as maintenance therapy in Crohn's disease. Available at: https://clinicaltrials.gov/ct2/show/NCT02611817. Last updated: November 12, 2019. Last accessed: February 2020.

4 Vedolizumab subcutaneous long-term open-label extension study. Available at: https://clinicaltrials.gov/ct2/show/NCT02620046. Last updated: May 6, 2019. Last accessed: February 2020.

5 Takeda Data on File. 2019.

6 Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.

7 Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590-1605.

8 Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18:1356-1363.

9 Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606-1619.

10 Feuerstein JD, Cheifetz AS. Crohn’s disease: Epidemiology, diagnosis and management. Mayo Clin Proc. 2017;92:1088-1103.

11 Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518-1532.

12 Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56:1536-1542.

13 Kaser A, Zeissig S, Blumberg RS. Genes and environment: How will our concepts on the pathophysiology of IBD develop in the future? Dig Dis. 2010;28:395-405.

14 Entyvio Prescribing Information. Available at: https://general.takedapharm.com/ENTYVIOPI. Last updated: May 2019. Last accessed: February 2020.

15 Entyvio EPAR _ 20/02/2019 Entyvio - EMEA/H/C/002782_ European Medicines Agency - Entyvio _ Annex I Summary of product characteristics. Committee For Medicinal Products For Human Use. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio. Last updated: April 2019. Last accessed: February 2020.

16 Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875.

17 Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97‑110.

18 Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its roles in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14:1298‑1312.

19 Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437-1444.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005188/en/

Contacts

Media Contacts:
Media outside Japan
Luke Willats
luke.willats@takeda.com
+41-44-555-1145

Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095


Permalink : https://www.aetoswire.com/news/takeda-receives-positive-chmp-opinion-for-subcutaneous-formulation-of-vedolizumab-for-use-as-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis-or-crohnrsquos-disease/en

Notice of ABB’s Annual General Meeting on March 26, 2020

ZURICH-Friday 28 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- ABB today published the invitation to its Annual General Meeting (AGM), which will be held on Thursday, March 26, 2020. The invitation can be found on ABB’s investor relations website at www.abb.com/agm.

ABB (ABBN: SIX Swiss Ex) is a technology leader that is driving the digital transformation of industries. With a history of innovation spanning more than 130 years, ABB has four, customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by the ABB Ability™ digital platform. ABB’s Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 144,000 employees. www.abb.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200227006109/en/

Contacts

ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland
Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com
or
Investor Relations
Phone: +41 43 317 71 11
Email: investor.relations@ch.abb.com

Permalink : https://www.aetoswire.com/news/notice-of-abbrsquos-annual-general-meeting-on-march-26-2020/en

Mavenir and MTI Announce First OpenRAN O-RAN Interface Remote Radio Unit (RRU) Portfolio

RICHARDSON, Texas-Friday 28 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Mavenir, the industry’s only end-to-end cloud-native, Network Software Provider and MTI announce the first commercial portfolio of OpenRAN RRUs with the O-RAN interface. The initial portfolio consists of 2x20W RRUs for B3, B20, B7 and 2x40W for B5, B28, B71 with general availability in Q2 2020. More variants and additional band support will be added over time.

This portfolio underpins the ability to start transitioning from walled garden systems based on proprietary interfaces to a wider, multi-supplier ecosystem that enables faster innovation and lower total cost of ownership, based on OpenRAN principles.

As the RRU is fully specified by 3GPP for the air interface and O-RAN for the RRU to DU interface, MNOs will have the ability to choose best-of-breed components and have the flexibility to choose from an increasing number of RRU and end-to-end vendors.

The key goals of OpenRAN are:

Open Interfaces
Increased Security
Increase RAN technology partner/supplier diversity
The RRU architecture is based on O-RAN Alliance Split 7.2 and all bands support 5G NR.

“Through this collaboration with MTI, we are bringing RRUs to the market with the latest features and competitive pricing. This is a game changer that levels the competition in both technical specification and price,” said Mikael Rylander, Mavenir’s SVP and GM, Radio Access Solutions. “Additionally, the wider ecosystem and open architecture principles not only allow a new alternative for traditional MNO deployments, but create new opportunities for flexible, cutting edge and cost-effective implementations for network densification, introduction of 5G, as well as deployments in enterprise and industry segments.”

“MTI now is delivering advanced remote radio units compliant with the O-RAN 7.2x functional split to provide an open and standardized interface solutions supporting the mobile network transformation to next generation RAN architecture,” said Allen Yen, Chairman & CEO of MTI.

About MTI

Microelectronics Technology Inc. (MTI) is a high-technology company that has specialized in wireless communication product development, manufacturing, and global sales for more than 35 years. Based on core competency in RF/ Microwave, MTI has established a leading position in the fields of Remote Radio Heads, Microwave Radios, Satellite Transceivers and ODUs, Broadband Wireless access products, and Radio Frequency Identification (RFID) readers and modules. With this excellent record of accomplishment, MTI has established valued, long-term partnerships with world-leading partners.

About Mavenir

Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation and revenue protection. Learn more at mavenir.com.

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.

Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005233/en/

Contacts
Maryvonne Tubb
Mavenir PR

NA-Loren Guertin
MatterNow

EMEA-Kevin Taylor
GlobalResultsPR




Permalink : https://www.aetoswire.com/news/mavenir-and-mti-announce-first-openran-o-ran-interface-remote-radio-unit-rru-portfolio/en

Mavenir Simplifies Deployment of 5G Cloud Solutions with Business Partners

VMware & Dell Technologies partner to enable focus on faster deployments with lower costs via containerized- and micro-serviced 5G end-to-end solutions

RICHARDSON, Texas-Friday 28 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Mavenir has announced integration of its 5G cloud-native telecom network functions (CNFs) with VMware’s container-ready Telco Cloud running on Dell Technologies’ edge computing solutions 5G deployments. Mavenir’s 5G deployments, pre-integrated and tested on Dell and VMware infrastructure will help speed deployments, simplify and reduce barriers for deploying 5G while providing new capabilities, including:

    Integration of open source Container as a Service (CaaS) and Platform as a Service (PaaS) with Mavenir’s microservices-based 4G/5G solutions including packet core and 4G/5G vRAN network functions and VMware’s Telco Cloud infrastructure. This allows Mobile Network Operators and Enterprises to quickly and easily deploy telco workloads on private or hybrid cloud environments by extending on-premises VMware vSphere-based environments to the AWS Cloud via VMware Cloud on AWS (https://cloud.vmware.com/vmc-aws).
    Acceleration of infrastructure modernization with Dell’s cloud-enabled mobile edge platforms that are tuned to host Mavenir’s 5G software solutions. The Dell Technologies edge computing solution with VMware Telco infrastructure helps speed onboarding and deployment of Mavenir’s high-performance containerized network functions (CNFs) and Virtual Network Functions (VNFs).
    VMware NSX-T Container Plug-in (NCP) providing integration between NSX-T and container orchestrators such as Kubernetes, as well as integration between NSX-T and container-based PaaS (platform as a service) products. The solution is orchestrated by VMware Telco Cloud Automation, with self-healing infrastructure and network function-aware closed loop automation.

The collaboration will allow Mobile Network Operators (MNOs) to deploy Mavenir’s market leading 4G/5G products and applications with VMware’s container technologies on Dell Technologies’ Telco cloud/edge computing infrastructure. The integrated solution is market ready for MNOs looking to either add 5G capabilities to an existing network or planning to launch a new 4G/5G network. Mavenir’s 4G/5G vRAN and Packet Core solutions are complemented with its market leading virtualized IMS based VoLTE, VoWiFi and Rich Messaging solutions to provide an end-to-end next generation network.

“The Mavenir/Dell/VMware solution utilizes end-to-end orchestration, closed loop automation mechanisms and harmonizing network slicing. Mavenir’s solution is designed to support applications and use cases that require millisecond latencies and responsive networks,” said Pardeep Kohli, Mavenir’s President and CEO.

“Mavenir is committed to lowering the TCO for operators through innovative solutions. Simplifying deployments with pre-integrated and tested solutions and aligned roadmaps is a key step towards that goal. The responsiveness and reliability expected from network clouds can now be realized from this solution,” said Bejoy Pankajakshan, Mavenir’s EVP and Chief Strategy Officer.

“By bringing our companies’ collective expertise in the telco industry, computing infrastructure and virtualized networking together, we are uniquely positioned to help Mobile Network Operators (MNOs), Communications Service Providers (CSPs), and enterprises transform their businesses,” said Gabriele Di Piazza, vice president, Solutions & Marketing, Telco and Edge Cloud, VMware.

“We believe the world is moving to software-defined everything, and compute infrastructure and networking plays a critical part. Dell Technologies' combined assets around Telco cloud Infrastructure, Open Networking, NSX, and Edge computing provide strong differentiation to our customers and partners like Mavenir, as a result, we are committed to this successful collaboration,” said Kevin Shatzkamer, vice president, Dell EMC Service Provider Strategy & Solutions.

About Mavenir

Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation and revenue protection. Learn more at mavenir.com.

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.

Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005128/en/

Contacts

Maryvonne Tubb
Mavenir PR

NA-Loren Guertin
MatterNow

EMEA-Kevin Taylor
GlobalResultsPR


Permalink : https://www.aetoswire.com/news/mavenir-simplifies-deployment-of-5g-cloud-solutions-with-business-partners/en

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

• Boehringer Ingelheim will work with Trutino Biosciences to access the company’s On-Demand-CytokineTM (ODC) platform to develop new cancer immunology compounds

• The partners aim to develop safer, more tolerable and more effective cytokine therapies for single agent and novel combinations with Boehringer Ingelheim’s innovative cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapies

INGELHEIM, Germany & SAN DIEGO, California-Friday 28 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform. Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of up to three new ODC candidates. This new collaboration combines Boehringer Ingelheim’s long-term strategy to provide first-in-class, breakthrough therapies for cancer patients with Trutino’s unique knowledge and expertise in increasing the safety and efficacy of cytokine therapies.

“Developing a strong and innovative cytokine therapeutic program as an additional component of our cancer immunology portfolio, demonstrates how we are ‘Taking Cancer On,’ and provides a high potential combination partner for our existing cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapeutics portfolio,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim. “We are very pleased to partner with Trutino and harness the potential of their innovative scientific platform to develop treatment breakthroughs that will transform the lives of cancer patients.”

Trutino’s ODC platform masks the activity of cytokines until they reach the tumor site and become fully activated, sparing systemic exposure and potentially leading to a higher margin of safety and greater efficacy than conventional cytokine treatments. Trutino will generate the new ODC molecules and carry out preclinical validation, handing over development to Boehringer Ingelheim for late pre-clinical testing through the rest of development.

“We are excited to embark on this partnership with Boehringer Ingelheim, a leader in cancer immunology, to advance cytokine therapeutic options that address the unmet medical needs of patients worldwide,” said Phillip Kim, Ph.D., MBA, Founder and CEO of Trutino Biosciences. “Boehringer Ingelheim has a deep commitment to innovative scientific approaches and is a leader in bringing novel cancer therapies to market. This global partnership validates the broad potential of our proprietary ODC platform to create safer and more effective cytokine therapies that can be delivered systemically and activated locally. Together, we can rapidly develop a new generation of cytokine therapies to address critical unmet need in oncology.”

Trutino’s clinical potential was initially recognized by Boehringer Ingelheim through its grass roots programs, including the ‘BI Innovation Prize,’ where the ODC platform technology was an early-stage standout in the 2019 program held in San Diego. Launched in 2015, the grass roots programs comprise of ‘BI Office Hours,’ ‘BI Academy’ and the ‘BI Innovation Prize.’ Through Office Hours, Boehringer Ingelheim has provided over 200 early-stage companies in the life-sciences community with mentoring and direct access to relevant expertise and industry perspective from senior leaders within the company. In partnership with BioLabs in Boston, New York and San Diego, Boehringer Ingelheim has awarded numerous entrepreneurs with free lab space through the ‘Golden Ticket’ program. As a company dedicated to improving health and quality of life, these programs give Boehringer Ingelheim the opportunity to lend expertise to the innovation community and offer guidance around the science to help enable ideas to deliver the next breakthroughs.

The partnership with Trutino will strengthen Boehringer Ingelheim’s next generation immune oncology portfolio, which combines cancer vaccines, oncolytic viruses, T Cell engagers and myeloid targeting platforms with the aim of making “cold” tumors that are invisible to the immune system “hot” to rally the immune system against the tumor. Under the terms of the agreement, Boehringer Ingelheim will provide an upfront payment, near-term pre-clinical milestone payments and clinical, regulatory and commercial milestone payments, including royalties on future product sales.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/cytokine-platform-collaboration-trutino-biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005580/en/

Contacts

For further information:

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
+49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
+1 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Trutino Bioscience
Phillip Kim
+1 858-880-5501
pkim@trutinobio.com

John Zacamy
+1 212-486-2760
info@trutinobio.com


Permalink : https://www.aetoswire.com/news/boehringer-ingelheim-enters-discovery-stage-collaboration-with-trutino-biosciences-to-grow-its-cancer-immunology-portfolio-with-novel-cytokine-platform/en

Tej Kohli Foundation Seeks to Incubate New Projects That Can Eliminate Corneal Blindness By 2035

Philanthropic Tej Kohli Foundation will establish a new incubator to back scientific projects and commercial ventures that are targeting new solutions.

Forms part of strategy by investor Tej Kohli to focus on new innovations borne from research, science, technology and enterprise for the prevention and cure of corneal blindness.

Solutions must be affordable, scalable and accessible in the poorest countries in the world, where 90% of those affected by blindness and visual impairment live.

LONDON-Monday 24 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capital will be available to both commercial and non-commercial projects that have a clear path to the prevention, treatment and cure of corneal blindness; with funding decisions based on the magnitude of the total impact that a project will likely have in poor and underserved communities worldwide by 2035, as well as the likelihood that a project will succeed.

The Tej Kohli Foundation continues to build its position as a multi-disciplinary global centre of focus for the development and advancement of an affordable, scalable and accessible ‘universal solution’ for preventing and eliminating corneal blindness. The World Health Organisation says that 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. Whilst approximately 75% of corneal disease is curable by corneal transplant, the costs of invasive surgery, and the many years of medicine needed to prevent rejection after surgery, makes this form of treatment entirely inaccessible to the majority of the people in the world who suffer from severe visual impairment or corneal blindness.

Tej Kohli co-founded the eponymous Foundation in 2005 alongside wife Wendy Kohli. He has previously spoken about funding life-changing corneal transplants in poor and underserved communities as being “like Schindler’s List, you do a few, then you just have to do more” (https://www.telegraph.co.uk/technology/2019/10/04/tej-kohli-indian-tech-billionaire-plans-turbocharge-britains/). In December 2019 the Tej Kohli Foundation announced that it had restored the sight of 5,736 blind people during the year (https://www.businesswire.com/news/home/20191219005417/en/5736-World%E2%80%99s-Poorest-People-Received-Gift-Sight) and committed $14m of further funding to its Cornea Institute.

Tej Kohli is also an evangelist of the opportunities that can be derived from the chain reaction of technological progression and the impact that they can have on human life: https://www.spearswms.com/billionaire-philanthropist-tej-kohli-ai/. The new Tej Kohli Foundation incubator hopes to back projects that can leverage this chain reaction of technological progression to develop and deliver new techniques and applications and game-changing innovations for improving access. The Foundation is seeking to incubate between one and three new projects initially, and welcomes funding applications from all fields of expertise. Projects must show that they can make a significant impact by 2035.

The Tej Kohli Foundation funded its first donor cornea implants at Niramaya Hospital in India in 2010. After funding thousands of corneal transplants, in 2015 the Tej Kohli Foundation substantially expanded its efforts to tackle corneal blindness in poor and underserved communities with the ambitious launch the Tej Kohli Cornea Institute in Hyderabad. Between January 2016 and November 2019 the Tej Kohli Cornea Institute welcomed more than 223,404 outpatients and completed more than 43,255 surgical procedures. The Tej Kohli Foundation has also pursued a ‘universal treatment’ for corneal blindness through its ‘Applied Research’ program, which is a longstanding scientific collaboration between researchers in Montreal Canada, and Moorfields Eye Hospital in the UK.

In January 2020 seed funding from the Tej Kohli Foundation was granted to two new research projects. The first project will focus on preventing corneal endothelial cell loss, which is usually permanent and is the leading reason for corneal transplantation worldwide. The second project will use novel drugs released by contact lenses to treat ocular surface pain and overcome the need for opioids when treating severe eye pain, which remains one of the unmet needs in Ophthalmology.

Eligible projects are invited to submit a 2-page project abstract as a PDF to: project2035@tejkohlifoundation.com. Submissions will be considered by the Tej Kohli Foundation on a case-by-case basis in direct collaboration with its global network of specialists.

Wendy Kohli, co-Founder of the Tej Kohli Foundation said:

“The YouTube channel of the Tej Kohli Foundation has many stories of individuals who have been cured of severe visual impairment or corneal blindness. But the overwhelming majority of those living needlessly with blindness still cannot afford or access treatment. It is only through major innovations borne from research, science, technology and enterprise that we can move toward a world where nobody is needlessly blind because of poverty.”

Tej Kohli, co-Founder of the Tej Kohli Foundation said:

“There are many innovations already in the pipeline that could one day offer affordable, scalable and accessible solutions for prevention and cure in the poor and underserved communities where corneal blindness is most pervasive. At the Tej Kohli Foundation we are interested in backing and funding new innovations and projects that will accelerate progress toward the goal of eliminating poverty-driven corneal blindness worldwide by 2035.”

About the Tej Kohli Foundation:

Website: http://www.tejkohlifoundation.com

YouTube: https://www.youtube.com/c/tejkohlifoundation

About Tej Kohli:

Profile: https://www.tejkohlifoundation.com/tej-kohli

Twitter: https://twitter.com/mrtejkohli

About Wendy Kohli:

Profile: https://www.tejkohlifoundation.com/wendy-kohli

View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005010/en/

Contacts
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
tejkohlifoundation@buchanan.uk.com
+44 207 466 5000

Permalink : https://www.aetoswire.com/news/tej-kohli-foundation-seeks-to-incubate-new-projects-that-can-eliminate-corneal-blindness-by-2035/en

Latest medical advancement that uses sound wave energy – Ultherapy

 The procedure is a non-invasive treatment with 100 percent success

Dubai, United Arab Emirates, -Thursday 27 February 2020 [ AETOS Wire ]

Aging can be partly chalked up to a loss of collagen production, which starts slowing down at a rate of 1 percent a year around age 38, gradually encouraging the skin to sag. To ensure that you maintain the slimming, tightening, and lifting - Ultherapy, a non-invasive way to firm areas like the chin, neck, brow, and décolleté is the best bet of the season. It's based on the same technology used in radiology for ultrasound imaging (i.e. during pregnancy).

While most procedures use radio frequency, Ultherapy uses sound wave energy to go through your skin to penetrate the muscle of the area you're treating, and the technology uses multiple attachments to allow for superficial, medium, and deep penetration. It causes the muscle to contract and shrink, which aesthetically results in a firming, wrinkle-smoothing, and contouring effect.

Given the advancement in medical science, it has been noted that 60 percent of cosmetic specialists now recommend the use of such non-invasive ultrasound therapies that have very little downtime.

According to Dr Manar Nasar of CosmeSurge, this non-invasive treatment is a perfect bet for younger patients who desire facial rejuvenation but aren’t quite ready for a facelift, and those who want to put off or avoid surgery. The treatment takes less than an hour and often delivers the skin-tightening improvement that patients are looking for, but some may require two session spaced six months apart for optimal results.

While most patients opt for this treatment in their early 30s or 40s, according to Dr Manar Nasar it is a good idea to get collagen-stimulating treatments in your 20s to mitigate future collagen loss. She believes that collagen gives the skin structure and prevents wrinkling, thus more collagen is always good for skin health which slows the aging process. As such, having these treatments when your body is still able to generate collagen theoretically will yield improved skin health long term. While this treatment is optimal for most patients, it is advised that individuals who suffer from pre-medical or skin conditions shouldn’t opt for this treatment as it might result in medical complications which can prove fatal for the patient.

Besides that, a key benefit of using Ultherapy is its ability to be non-invasive without the potential side effects of anaesthesia or unforeseen complications associated with post-procedure healing. Another feature of the treatment is the ultrasound imaging which allows the doctor visualize the lower layers of the skin. This means the heat can be directed to the precise locations that are in most need of improvement and avoids nerve damage, leading to 100 percent success.

With January being the busiest time for aesthetic procedures, now is the time men and women opt for Ultherapy. However, as always, it is recommended that seek a certified medical professional if you’re considering any collagen-stimulating treatments.

Contacts

SAHARA Management Consultancy

Maria Tayem, Senior Account Manager, +971501714347, +97143298996
m.tayem@saharapr.com / www.saharagcc.com

Permalink : https://www.aetoswire.com/news/latest-medical-advancement-that-uses-sound-wave-energy-ndash-ultherapy/en

Mavenir Collaborates with Partners to Launch the Evenstar Remote Radio Head (RRH) Family

 Aim is to accelerate the adoption of Open RAN technology.



RICHARDSON, Texas-Thursday 27 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Mavenir, an industry-leading end-to-end cloud-native network software provider for CSPs, announced today the launch of the Evenstar Remote Radio Head (RRH), in collaboration with Facebook Connectivity, MTI, Deutsche Telekom and other partners. The goal of the program is to accelerate the adoption of Open RAN technology.

The Evenstar program will contribute to the OpenRAN ecosystem by focusing on building general-purpose RAN reference designs for 4G and 5G networks that are aligned with 3GPP and O-RAN specifications and will help accelerate the adoption of TIP OpenRAN Project Group Solutions. RRHs, distribution units, and control unit software have traditionally been only available as a packaged unit, limiting opportunities to serve suburban and rural locations. By decoupling these components, the Evenstar program is expected to enable MNOs to choose best-in-class technology and deploy solutions from an increasing number of technology partners.

The Evenstar family is expected to eventually include multiple Remote Radio Head (RRH) product SKUs, including FDD B3 (4T4R 4X40W) and B28 2T4R 2x80W. The RRH architecture is based on O-RAN Alliance Fronthaul specifications based on Split 7.2.

"The Evenstar program is supported by a group of like-minded organizations that share a common goal of accelerating the adoption of Open RAN. Through this collaboration, we hope to release RRHs with the latest features and competitive pricing. The Evenstar RRH and the program itself will help level the competition in both technical specification and price," said Mikael Rylander, SVP and GM of the Radio Access Business Unit at Mavenir.

“With Project Evenstar, Facebook Connectivity is collaborating with Mavenir and other ecosystem organizations to support building RAN hardware components for 4G and 5G networks,” said Dan Rabinovitsj, Vice President for Facebook Connectivity. “A healthy ecosystem of OpenRAN vendors plays an important role in emerging deployments for 4G and 5G networks based on open architectures addressing various deployment scenarios and use cases.”

“As one of the Evenstar partners, MTI is honored to deliver a reliable and advanced RRH solution for the innovative open ecosystem with the integration of our digital and RF technology and the O-RAN 7.2x functional split,” said Allen Yen, Chairman & CEO of MTI.

“To benefit from next generation, open, disaggregated RAN solutions that can be implemented in various deployment scenarios for 4G and 5G networks, it is important for Deutsche Telekom to work with innovative partners driving O-RAN compliant technology,” says Abdurazak Mudesir, SVP Technology Architecture & Innovation, Deutsche Telekom. “This collaboration between the O-RAN and TIP communities is an important contribution to grow that ecosystem and accelerate the commercialization of Open RAN technology.”

The Evenstar RRH will be available in mid-2020 as part of the Evenstar program with plans to expand into other Open RAN architectural elements.

For more information: https://telecominfraproject.com/tip-community-momentum-driven-by-new-operator-demand-technology-solutions-and-industry-alliances/

About MTI

Microelectronics Technology Inc. (MTI) is a high-technology company that has specialized in wireless communication product development, manufacturing, and global sales for more than 35 years. Based on core competency in RF/ Microwave, MTI has established a leading position in the fields of Remote Radio Heads, Microwave Radios, Satellite Transceivers and ODUs, Broadband Wireless access products, and Radio Frequency Identification (RFID) readers and modules. With this excellent record of accomplishment, MTI has established valued, long-term partnerships with world-leading partners.

About Facebook Connectivity

Connectivity is at the heart of Facebook’s mission to give people the power to build community and bring the world closer together. Critical to this mission is high-quality internet access, which gives people a voice and creates opportunities to share knowledge that can strengthen local communities and global economies. Facebook Connectivity works closely with partners including mobile network operators, equipment manufacturers and more to develop programs and technologies—including Express WiFi, Magma, and Terragraph—that increase the availability, affordability and awareness of high-quality internet access, bringing more people online to a faster internet. To learn more, visit: https://connectivity.fb.com.

About Mavenir

Mavenir is the industry’s only End-to-End, Cloud Native Network Software Provider, redefining network economics for Communication Service Providers (CSPs). Our innovative solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to CSPs for revenue generation, cost reduction, and revenue protection. For more information, visit: www.mavenir.com.

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.

Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005663/en/

Contacts

Maryvonne Tubb
Mavenir PR

NA-Loren Guertin
MatterNow

EMEA-Kevin Taylor
GlobalResultsPR


Permalink : https://www.aetoswire.com/news/mavenir-collaborates-with-partners-to-launch-the-evenstar-remote-radio-head-rrh-family/en

Velodyne Lidar Announces Sales Agreement With Idriverplus

Idriverplus Moving to Mass Production of Its Autonomous Street Cleaning Vehicles – Equipped With Velodyne Lidar Sensors

SAN JOSE, Calif.-Thursday 27 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Velodyne Lidar, Inc. today announced a sales agreement with Idriverplus to provide Puck™ sensors over three years. Idriverplus will use Velodyne lidar sensors in mass production of its commercial autonomous vehicles, including street cleaners, passenger cars and logistics vehicles.

This year, Idriverplus plans to place into commercial operation in China thousands of units of its unmanned, electric street cleaning vehicles, called WOXIAOBAI, with each vehicle equipped with two Puck sensors to ensure security and perception. Idriverplus vehicles are being used to clean and disinfect hospital areas as part of efforts to combat the coronavirus epidemic in China.

Idriverplus is also developing two autonomous car solutions; an SAE Level 4 vehicle designed to drive in closed parks and some public roads, and an advanced driver assistance system (ADAS) for automatic parking (AVP) and highway follow-up (HWP). The company’s WOBIDA product applies self-driving technology to the logistics industry, providing a safer and better last mile delivery experience.

Idriverplus was the first company in China to mass produce driverless products and receive orders for 1,000 driverless vehicles. The company’s founders all come from Tsinghua University, China’s leading research university.

“We selected Velodyne sensors because of the outstanding lidar quality and mass production scale they provide,” said Idriverplus CEO Dr. Zhang Dezhao. “Our successful experience working with Velodyne lidar shows it delivers cutting-edge performance. Teaming with Velodyne will help us achieve our goal of high-volume manufacturing of commercial autonomous vehicles.”

“Idriverplus has a talented technical team that is leading the way in driverless technology commercialization,” said Wei Weng, Executive Director of Asia, Velodyne Lidar. “Their autonomous vehicles demonstrate how Velodyne lidar sensors address the production and scalability requirements needed for mass deployments. We have confidence in the China market and are honored to work with companies like Idriverplus to help them be successful in autonomous vehicle deployment.”

Velodyne Puck sensors provide rich computer perception data that allows real-time object and free space detection needed for safe navigation and reliable operation. The Puck is a small, compact lidar sensor that delivers 100 meters range. Its reliability, power-efficiency and surround view make it an ideal solution for affordable low speed autonomy applications.

About Velodyne Lidar

Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005188/en/

Contacts

Sean Dowdall
Landis Communications Inc. for Velodyne Lidar, Inc.
(415) 286-7121
velodyne@landispr.com

Permalink : https://www.aetoswire.com/news/velodyne-lidar-announces-sales-agreement-with-idriverplus/en

AIG Appoints Jon Hancock Chief Executive Officer, International General Insurance

LONDON -Thursday 27 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- American International Group, Inc. (NYSE:AIG) today announced that Jon Hancock has been appointed Chief Executive Officer, International General Insurance. In this role, Mr. Hancock will lead the International operations of AIG’s General Insurance business. He will report to Peter Zaffino, President & Global Chief Operating Officer, AIG, and Chief Executive Officer, General Insurance, and serve on the General Insurance Executive Leadership Team. Mr. Hancock will join the company this spring.

Since 2016, Mr. Hancock served as Director of Performance Management at Lloyd’s, where his portfolio included responsibility for overseeing performance and risk management globally across the Lloyd’s market.

“Jon is a seasoned executive and industry leader recognized for his track record of underwriting excellence and delivering strong financial results,” said Mr. Zaffino. “Jon’s deep technical expertise and significant international operating experience ideally qualify him for this important leadership role.”

“I am pleased to join AIG as the company continues its remarkable progress towards being a top performing company,” said Mr. Hancock. “I look forward to working with AIG’s talented colleagues around the world to enhance the value we deliver to clients as we position the company for sustained profitable growth.”

Prior to Lloyd’s, Mr. Hancock spent 26 years at RSA in roles of increasing responsibility, including serving as Managing Director, UK Commercial, which encompassed RSA’s European Specialty businesses, and Global Broker Relationship Director. Previously, he served as RSA’s Chief Executive Officer, Asia and Middle East, and held chief underwriter and risk roles in both developed and emerging markets.

American International Group, Inc. (AIG) is a leading global insurance organization. AIG member companies provide a wide range of property casualty insurance, life insurance, retirement solutions, and other financial services to customers in more than 80 countries and jurisdictions. These diverse offerings include products and services that help businesses and individuals protect their assets, manage risks and provide for retirement security. AIG common stock is listed on the New York Stock Exchange.

Additional information about AIG can be found at www.aig.com | YouTube: www.youtube.com/aig | Twitter: @AIGinsurance www.twitter.com/AIGinsurance | LinkedIn: www.linkedin.com/company/aig. These references with additional information about AIG have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

AIG is the marketing name for the worldwide property-casualty, life and retirement, and general insurance operations of American International Group, Inc. For additional information, please visit our website at www.aig.com. All products and services are written or provided by subsidiaries or affiliates of American International Group, Inc. Products or services may not be available in all countries and jurisdictions, and coverage is subject to underwriting requirements and actual policy language. Non-insurance products and services may be provided by independent third parties. Certain property-casualty coverages may be provided by a surplus lines insurer. Surplus lines insurers do not generally participate in state guaranty funds, and insureds are therefore not protected by such funds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005627/en/

Contacts

Sabra Purtill (Investors): +1 212-770-7074; sabra.purtill@aig.com
Hannah Scott (Media): +44 20 7954 7289; hannah.scott@aig.com
Matt Gallagher (Media): +1 212-458-3247; matthew.gallagher2@aig.com

Permalink : https://www.aetoswire.com/news/aig-appoints-jon-hancock-chief-executive-officer-international-general-insurance/en

Andersen Global Premieres in Sierra Leone, Continuing Its Expansion Efforts in Africa

SAN FRANCISCO-Thursday 27 February 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- Andersen Global is strengthening its presence in West Africa with a Collaboration Agreement with Freetown-based legal firm Fornah-Sesay, Cummings, Showers & Co. (hereinafter referred to as FCS Legal) in Sierra Leone, adding depth to its global platform on the continent.

FCS Legal has been advising clients for over 15 years led by Office Managing Partner James Fornah-Sesay and more than 10 legal professionals. The firm provides legal services for corporate institutions and individuals in the areas of banking and finance, construction and engineering, corporate and commercial, energy, environmental, pharmaceutical, oil and gas, real estate, tax and telecommunications.

“We pride ourselves in prioritizing our clients’ needs as well as maintaining excellent working relationships with key players in Sierra Leone’s public, private and legal sectors,” James said. “Our collaboration with Andersen Global will allow us to expand our global reach and better serve our clients by bringing them the resources of a global firm in a seamless manner.”

Mark Vorsatz, Andersen Global Chairman and Andersen CEO added, “FCS Legal is one of the fastest-growing and largest firms in the market. It was immediately clear they possess a passion for providing their clients with best-in-class services, while prioritizing their dedication to stewardship and transparency.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 5,000 professionals worldwide and a presence in over 167 locations through its member firms and collaborating firms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005013/en/

Contacts

Megan Tsuei
Andersen Global
415-764-2700


Permalink : https://www.aetoswire.com/news/andersen-global-premieres-in-sierra-leone-continuing-its-expansion-efforts-in-africa/en

Orange and SES Team up on O3b mPOWER Communications System and Open a New Era for Satellite Connectivity Innovation

Orange will be the first global telecom operator to integrate satellite-based revolutionary terabit-scale O3b mPOWER communications system in its network, to support the growing demand for connectivity in Africa


PARIS & LUXEMBOURG -Thursday 27 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Orange, one of the world’s leading multi-service telecommunications operators and present in 18 countries in Africa, will be the first telco to adopt the ground-breaking O3b mPOWER, SES’s next-generation Medium Earth Orbit (MEO) satellite communications system, to exponentially ramp up its consumer and business services, starting in the Central African Republic.

O3b mPOWER is the world’s only fully-funded non-geostationary orbit (NGSO) broadband system in development today. Positioned at only 8,000 kilometres away from Earth, the system will power low-latency high-throughput solutions that can be seamlessly integrated into existing terrestrial networks. When operational in 2022, O3b mPOWER will provide multiple terabits of throughput globally to drive digital transformation and cloud adoption virtually anywhere on the planet.

The highly flexible O3b mPOWER constellation comprises ultra-high-capacity, low-latency, high-power MEO satellites, each with up to 5,000 fully-shapeable and steerable beams that can be shifted and scaled in real-time to meet customers’ demands. The system is ideally suited for domestic cellular backhaul and simultaneous international IP trunking applications.

Orange has been a customer and early adopter of SES’s current generation O3b MEO managed services since 2017. Orange is a strategic partner for SES with its large presence in Africa and the Middle East, and with satellite gateways in several countries on the continent. With O3b mPOWER, Orange will substantially increase its low-latency MEO-enabled capabilities to support the growth of its bandwidth demand, driven by the ever-growing customer base, the new digital uses and financial services. The revolutionary system will enable Orange to offer high broadband and seamless connectivity, while extending geographical reach.

In addition, Orange Central African Republic will leverage the world’s only multi-orbit network, utilising SES’s MEO and GEO (Geostationary Earth Orbit) satellites to connect and aggregate 2G/3G traffic from remote base stations around the country to the core network in the capital of Bangui. This gives the operator a single source for cellular backhaul and core IP transit, as well as a consistent and seamless experience between the MEO and GEO services.

“We are thrilled to be partners and early adopters of this innovation with SES, and to be able to offer high-quality connectivity in the most remote locations of the Central African Republic. This longstanding partnership fully aligns with our mission of building smarter and open networks to bridge the digital divide in Africa, and to increase the speed and geographic reach of our network,” said Jean-Luc Vuillemin, Executive Vice President at Orange International Networks Infrastructures and Services.

“This new agreement marks a very important milestone for both our companies and also for the broader industry. With the innovative O3b mPOWER system, Orange and SES are revolutionising the telco market, and the way networks can be extended and improved,” said JP Hemingway, CEO of SES Networks. “With its ability to power a wide range of telecommunications needs, including cellular backhaul and high-performance cloud connectivity, O3b mPOWER – together with other terrestrial infrastructure – is key to connecting remote and underserved regions in the most economically viable way.”

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of over 355 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226006105/en/

Contacts

Suzanne Ong
Public Relations, SES
Tel. +352 710 725 500
suzanne.ong@ses.com



Permalink : https://www.aetoswire.com/news/orange-and-ses-team-up-on-o3b-mpower-communications-system-and-open-a-new-era-for-satellite-connectivity-innovation/en

Bioventus Recognizes 25 Years of Proven Bone Healing from EXOGEN

DURHAM, N.C -Thursday 27 February 2020 [ AETOS Wire ]

(BUSINESS WIRE)--Bioventus, a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System. EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process and promote fracture healing. It has an 86% heal rate for fractures not healing on their own1 and provides 38% faster healing of indicated fresh fractures.2, 3

Since its launch in 1995, EXOGEN has been used to treat more than 1 million patients worldwide. Today it is prescribed by over 10,000 physicians annually4 and is sold in 15 countries. Backed by 16 Level 1 studies proving its safety and efficacy, 5-20* EXOGEN is used by patients at home and at their convenience for just 20 minutes a day.

“The numbers tell such a compelling story and represent an incredible milestone for Bioventus and EXOGEN,” said Tony Bihl, CEO, Bioventus. “It’s a great product with proven outcomes and for the last 25 years, it has healed nonunion and acute fractures for patients worldwide. This level of success and longevity was made possible by the tireless efforts of our employees and treating clinicians.”

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on LinkedIn and Twitter.



Bioventus, the Bioventus logo, and EXOGEN are registered trademarks of Bioventus LLC.



Summary of Indications for Use

EXOGEN is indicated for the non-invasive treatment of established nonunions† excluding skull and vertebra. The EXOGEN device has also been reported as effective as an adjunctive non-invasive treatment of established nonunions† in patients:

    With internal or external fracture fixation hardware present. EXOGEN cannot penetrate metal and therefore should not be applied directly over hardware.

    Undergoing treatment for infection at the fracture site. EXOGEN is not intended to treat the infection.

    Believed to have diminished bone quality. EXOGEN is not intended to treat diminished bone quality.

EXOGEN is also indicated for the acceleration of fresh fracture heal time, repair following osteotomy, repair in bone transport procedures and repair in distraction osteogenesis procedures. There are no known contraindications for the EXOGEN device. Safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, on fractures due to bone cancer, or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling at exogen.com or by calling Bioventus Customer Service at 800-836-4080. † A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing.

1.
   

Nolte PA, van der Krans A, Patka P, Janssen IM, Ryaby JP, Albers GH Low-intensity pulsed ultrasound in the treatment of non-unions. J Trauma. 2001; 51(4):693−703.

2.
   

Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF Acceleration of tibial fracture-healing by non- invasive, low intensity pulsed ultrasound. J Bone Joint Surge [Am].1994; 76(1):26−34.

3.
   

Kristiansen TK, Ryaby JP, McCabe J, Frey JJ, Roe LR Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multicenter, prospective, randomized, double-blind, placebo controlled study. J Bone Joint Surg [Am]. 1997; 79(7):961−973.

4.
   

Bioventus, Data on File, RPT-000965 [A]

*The Journal of Bone & Joint Surgery Level of Evidence 2015 Ratings Table was used to define the level of each clinical study. Levels of Evidence for Primary Research Question, J Bone Joint Surg Am. 2015;97(1)1-2. These studies, which reflect the body of evidence for EXOGEN, include evaluations of applications outside the approved labeling.

5.
   

Dudda M, Hauser J, Muhr G, Esenwein SA. J Trauma. 2011;71(5):1376-80.

6.
   

El-Mowaf H, Mohsen M. Int Orthop. 2005;29(2):121-4.

7.
   

Emami A, Petrén-Mallmin M, Larsson S. J Orthop Trauma. 1999;13(4):252-7.

8.
   

Handolin L, Kiljunen V, Arnala l, et al. J Orthop Sci. 2005;10(4):391-5.

9.
   

Handolin L, Kiljunen V, Arnala I, Pajarinen J, Partio EK, Rokkanen P. Arch Orthop Trauma Surg. 2005;125(5):317-21.

10.
   

Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF. J Bone Joint Surg Am. 1994;76(1):26-34.

11.
   

Kristiansen TK, Ryaby JP, McCabe J, Frey JJ, Roe LR. J Bone Joint Surg Am. 1997;79(7):961-73.

12.
   

Leung KS, Lee WS, Tsui HF, Liu PP, Cheung WH. Ultrasound Med Biol. 2004;30(3):389-95.

13.
   

Lubbert PH, van der Rijt RH, Hoorntje LE, van der Werken C. Injury. 2008;39(12):1444-52.

14.
   

Mayr E. Rudzki MM, Rudzki M, Borchardt B, Häusser H, Rüter A. Handchir Mikrochir Plast Chir. 2000;32(2):115-22.

15.
   

Rue JP, Armstrong DW 3rd, Frassica FJ, Deafenbaugh M, Wilckens JH. Orthopedics. 2004;27(11):1192-5.

16.
   

Salem KH, Schmelz A. Int Orthop. 2014;38(7):1477-82.

17.
   

Strauss E, Ryaby JP, McCabe J. J Ortho Trauma. 1999;13(4):310.

18.
   

Tsumaki N, Kakiuchi M, Sasaki J, Ochi T, Yoshikawa H. J Bone Joint Surg Am. 2004;86- A(11):2399-405.

19.
   

Zacherl M, Gruber G, Radl R, Rehak PH, Windhager R. Ultrasound Med Biol. 2009;35(8):1290-7.

20.
   

Schofer MD, Block JE, Aigner J, Schmelz A. BMC Musculoskelet Disord. 2010;11(1):229. doi: 10.1186/1471-2474-11-229.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005164/en/

Contacts

Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com

Permalink : https://www.aetoswire.com/news/bioventus-recognizes-25-years-of-proven-bone-healing-from-exogen/en

Analogix ANX7580 Display Controller Empowers LG Dual Screen Handheld Mobile Applications

SANTA CLARA, Calif.-Thursday 27 February 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- Analogix Semiconductor, Inc. today announced that its SlimPort® ANX7580 DisplayPort™ to MIPI-DSI display controller has been implemented in multiple devices, the most recent being the LG V60 ThinQ and the Dual Screen, as well as in various handheld PC gaming devices.

With a 4-lane DisplayPort 1.4 input and 4 MIPI lanes for a single panel, the ANX7580 connects to graphics processing units (GPUs), both embedded and discreet, and to MIPI displays used in dual clamshell display applications today. These applications benefit from the following ANX7580 key advantages:

    Support for DisplayPort and embedded DisplayPort (eDP);

    Support for ARM, x86, and other computing architectures;

    High-bandwidth Digital Content Protection (HDCP) support such as video content protection and Hi-Fi audio;

    Small footprint (4x4 mm2) and low power (<150mW) architecture;

    Turn-key reference design for fast time-to-market.

“Innovation and refinement drive our roadmap to create products that enable our OEM customers’ success,” said Michael Ching, vice president of marketing at Analogix. “They can create differentiated dual screen applications to satisfy the most extreme multitaskers. One can open independent applications on either screen or extend an application across both screens. Gamers can use one screen as a control pad, while multitaskers can work with two apps simultaneously. An advantage of this form factor is that the dual screen accessory can be put on when needed and slid the phone out of when not.”

The ANX7580 is in mass production.

About Analogix Semiconductor

Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones, notebooks, and AR/VR head mounted displays, to large, high-definition TVs and high-end graphics cards. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort under its SlimPort brand, including high-speed signal conditioners, and an industry leader in display panel controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector.

Analogix display panel timing controllers offer the world’s lowest power, smallest packaging, and proprietary image enhancement to produce more accurate colors, thinner bezels, and smoother frame rates on the latest high dynamic range (HDR) panels.

For more information visit www.analogix.com and www.slimport.com, follow us on Twitter @Analogix and @SlimPortConnect, or connect with us on LinkedIn.

Analogix and SlimPort are trademarks or registered trademarks of Analogix Semiconductor, Inc. All other trademarks and trade names are the property of their respective owners.

Category: Corporate News

Product News

Photos/Multimedia Gallery Available: https://www.businesswire.com/news/home/52177697/en

Contacts

Michael Ching
Tel: 408-988-8848
marcom@analogix.com

Permalink : https://www.aetoswire.com/news/analogix-anx7580-display-controller-empowers-lg-dual-screen-handheld-mobile-applications/en